Lisdexamfetamine dimesylate

Details

Files

Generic Name:

Lisdexamfetamine dimesylate

Project Status:

Complete

Therapeutic Area:

Attention deficit hyperactivity disorder

Manufacturer:

Shire Canada Inc.

Brand Name:

Vyvanse

Project Line:

Reimbursement Review

Project Number:

SR0171-000

Submission Type:

Initial

Indications:

Attention deficit hyperactivity disorder

Recommendation Type:

Do not list

Final Recommendation:

December 18, 2009

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Last Updated : July 10, 2009